Archive for the 'Trimodality Therapy' Category
Preoperative chemotherapy and postoperative radiation.
December 6th, 2005. Multimodality treatments in the management of malignant pleural mesothelioma: an update
In most cases there is no sufficient time for systemic disease to develop or contribute to mortality. The first order of therapy in MPM is currently, as it has been for decades, to control effectively the tumor's locoregional spread and then deal with controlling the distant disease.
November 30th, 2005. Carcinoma of the jejunum with multideposit peritoneal seeding, resection and intraperitoneal chemotherapy
This condition is reviewed along with the rationale for IPC. keywords: Carcinoma, jejunum, multideposit peritoneal seeding, resection, intraperitoneal, chemotherapy.
November 16th, 2005. Partial, but not Complete, Tumor-Debulking Surgery Promotes Protective Antitumor Memory when Combined with Chemotherapy and Adjuvant Immunotherapy
Partial debulking followed by combination therapy elicited the same proportion of cured animals but in contrast to complete resection, a memory response was invoked. We postulate that chemotherapy induced apoptosis of the residual tumor cells following incomplete resection is absolutely required for the induction of long-term immunologic memory.
October 7th, 2005. Recent progress in treatment of malignant pleural mesothelioma
Multimodality therapy with extrapleural pneumonectomy and radiation therapy (+/-chemotherapy) can be of benefit in subgroups of patients but it cannot be recommended in a routine approach. As compared to bronchial carcinoma, inclusion of patients in clinical trials (using intensity-modulated radiation therapy) is the only way to somewhat improve results.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Extrapleural Pneumonectomy (EPP), Full Archive, IMRT, Pemetrexed (Alimta), Pleural, Radiation, Surgery, Treatment, Trimodality Therapy, Type of Assessment:, Type of Mesothelioma: | No Comments »
July 1st, 2005. Photodynamic therapy as an adjunct to surgery for malignant pleural mesothelioma
Experimental work on MPM has shown that tumor selectivity of PDT depend on treatment conditions and can be improved by structural modification and improved targeting of the sensitizers. Refinements of PDT for mesothelioma will depend on a more detailed understanding of the pathways for preferential sensitizer accumulation within the tumor as well as on synergistic effects between PDT and chemotherapeutic agents.
May 1st, 2005. Therapeutic options in malignant pleural mesothelioma
Radiotherapy may be applied in case of local tumour growth. The individual therapeutic decision will depend on tumour stage, concomitant diseases, performance status, and on the patient's preference.
Posted in Cisplatin (Platinol ®), Determining Efficacy, EGFR, Extrapleural Pneumonectomy (EPP), Full Archive, Pemetrexed (Alimta), Pleural, Pneumonectomy, Radiation, Surgery, Treatment, Trimodality Therapy, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
May 1st, 2005. P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma
Conclusions: Biphasic histology, increased mitotic rate, and p16 loss were independently associated with poorer survival in peritoneal malignant mesothelioma. Among the trimodal treated patients, increased mitotic rate was associated with increased risk of death.
April 7th, 2005. Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan-Kettering experience
This combined modality approach is feasible for locally advanced MPM, and initial analysis suggests improved resectability. This experience supports additional studies of induction and multimodality therapy, especially with regimens such as cisplatin and pemetrexed which may be better tolerated and more effective.
November 1st, 2004. Patterns of failure following surgical resection for malignant pleural mesothelioma
Further clinical studies are needed for all patients with mesothelioma to define the optimum surgery and duration and types of adjuvant therapy. The appropriate multimodality approaches most likely will differ based on disease stage, histology, and patient performance status.
Posted in Chemotherapy, Cisplatin (Platinol ®), Extrapleural Pneumonectomy (EPP), Full Archive, Gemcitabine (Gemzar), Intraperitoneal Chemotherapy, Intrapleural Chemotherapy, Pemetrexed (Alimta), Pleural, Pleurectomy/decortication, Radiation, Surgery, Survival, Treatment, Trimodality Therapy, Type of Assessment:, Type of Mesothelioma: | No Comments »
September 25th, 2004. Pleural mesothelioma: little evidence, still time to do trials
Survival is short and the treatments on offer are onerous. The only responsible approach from a scientific, compassionate, or economic view (and why not combine all three?) is to find evidence of effectiveness to avoid futile and distressing treatment when possible.
|
|  |
